Rescriptor (Delavirdine)

The Basics | Research

Brand Name:	Rescriptor
Generic Name:	Delavirdine, DLV
Adult Single Dose:	Two 200-mg tablets (three times a day) OR four 100-mg tablets (three times a day)
Food & Liquid Restrictions:	None
Drug Class:	NNRTI

The Basics

Delavirdine (Rescriptor) (November 28, 2012)
To read PDF, click here.
From AIDS InfoNet
An Overview of Rescriptor (Delavirdine) (September 13, 2012)
From AIDSinfo
Rescriptor (March/April 2012)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
Patient Information About Rescriptor (Delavirdine) (PDF) (September 2010)
From ViiV Healthcare
Rescriptor (Delavirdine) (September 28, 2007)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
Delavirdine (Rescriptor) (November 13, 2006)
From AIDSmeds.com
Rescriptor (Delavirdine) (May 2005)
To read PDF, click here.
From The Center for AIDS
Drug Interactions: Delavirdine (August 2004)
From Project Inform

News

Delavirdine (Rescriptor) Approved (April 1997)
From AIDS Treatment News
Delavirdine Approved: The Difficult Task of Finding a Role for the Latest NNRTI (April/May 1997)
In GMHC Treatment Issues, from Gay Men's Health Crisis

Research

Women and Pharmacology: Delavirdine Study (March 2001)
In Project Inform Perspective, from Project Inform
Therapeutic Drug Monitoring of Amprenavir Combined With Ritonavir as Salvage Therapy in HIV-1-Infected Patients (July 11, 2000)
In The XIII International AIDS Conference, from TheBodyPRO.com
ACTG 359: A Chain Reaction of Unintended Consequences (July 2000)
Unexpected adefovir/delavirdine interaction found to reduce delavirdine/saquinavir levels.
In TAGline, from Treatment Action Group
Continued Lamivudine (3TC) vs. Delavirdine (DLV) in Combination With Indinavir (IDV) and Zidovudine (ZDV) or Stavudine (d4T) in 3TC-Experienced Patients: 48-Week Follow-Up of ACTG 370 (February 1, 2000)
In The 7th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
Delavirdine Combination and Viral Load (October 17, 1997)
In AIDS Treatment News, from AIDS Treatment News
Antiretroviral Drug Interaction Studies Show Favorable Effects (January 1997)
Includes a brief look at drug-interaction studies for delavirdine-saquinavir and delavirdine-indinavir.
In The 4th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
Delavirdine Disappoints at FDA (January 1997)
In TAGline, from Treatment Action Group

TheBody.com App for iPhones

My Health Tracker

Medication and Health Reminders

Assess Your Risk for HIV

U.S. ASO Finder

Newly Diagnosed? Words of Encouragement from HIV-Positive Women

HIV Management Today: Mental Health & HIV, the Uncharted Territory

Curing HIV Removes the Scars of the Past

Meth Makes an Ominous Comeback Among Gay Men

Can HIV-Positive People Have Babies? 7 Myths About Pregnancy and HIV/AIDS

More >>

The Body is a service of Remedy Health Media, LLC, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.